Anti-Asthmatics And COPD Drugs Emerged As The Largest Segment In RespiratoryPosted by sainath on December 19th, 2018 The global respiratory diseases drugs market, one of the segments of healthcare industry. During the historic period it grew at a compound annual growth rate (CAGR) of around 6.5%. This was mainly due to the increased air pollution which will lead to increased respiratory diseases. For the forecasted period, the respiratory market size is expected to be over USD70 billion by 2021, growing at a CAGR of nearly 6.5%. The growth rate for forecasted period is higher when compared to the historic period. This is mainly attributed to the rise in global air pollution levels which will lead to higher number of respiratory diseases thus driving the respiratory drugs market. Find TBRC’s report on the Respiratory Drugs market: Anti-Asthmatics And COPD Drugs was the largest segment in the respiratory drugs market accounting for 65% of the market. This segment includes companies that produce drugs that can be used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings. Some of the major anti-asthmatics and COPD drugs include antimuscarinics, corticosteroids, leukotriene inhibitors, xanthines, albuterol (Vospire ER), levalbuterol (Xopenex), ipratropium (Atrovent).xxxiv The large size of this segment was due to increasing number of patients of asthma and COPD caused by tobacco smoking and air pollution. Download a sample report: https://www.thebusinessresearchcompany.com/sample.aspx?id=282&type=smp About The Business Research Company. The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally. Contact Information. The Business Research Company Europe: +44 207 1930 708 Asia: +91 8897263534 Americas: +1 315 623 0293 Email: info@tbrc.info Like it? Share it! More by this author |